Johnson & Johnson (JNJ)
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of care in certain NSCLC patients.
Procter & Gamble, Johnson & Johnson Among 10 Companies To Announce Dividend Increases In First Half Of April
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. A slow March brought mid-single digit percentage dividend boosts from consumer goods company Colgate-Palmolive and defense contractor General Dynamics. Widely-held Johnson & Johnson, Procter & Gamble, and Costco will announce increases in the first half of April.
Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)
Two recent catalysts, one technical and one fundamental, have promoted me to adjust my rating on JNJ to a HOLD from my earlier buy rating. Technical trading patterns signal that JNJ is entering a consolidation phase with no clear directional momentum in the near term. In the meantime, JNJ's valuation ratios have expanded, narrowing the discount compared to historical averages and shifting its return/risk profile.
Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally promoting the HIV drugs Prezista and Intelence.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
2 Recession-Proof Dividend Stocks to Buy and Hold
Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's not a bad idea for investors to purchase shares of companies that are likely to perform relatively well in case it does happen.
The Big 3: JNJ, GE, LULU
Healthcare headwinds have @Theotrade's Don Kaufman leaning bearish on Johnson & Johnson (JNJ) while staying bullish in GE Aerospace (GE) despite hitting 18-year highs today. He offers options trades in those companies alongside an earnings play for Lululemon (LULU).
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
The latest trading day saw Johnson & Johnson (JNJ) settling at $163.29, representing a -0.21% change from its previous close.
Here's How to Play JNJ Stock as it Announces $55B US Investment Plan
Those who own JNJ stock may stay invested for some time, as the company is optimistic about a better performance in 2025.
J&J to Invest $55B in United States to Boost Manufacturing, R&D
JNJ announces plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States.
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV) induction options, for adults with moderately to severely active Crohn's disease (CD), a chronic inflammatory condition of the gastrointestinal tract.
